Vertex Pharmaceuticals logo

Vertex Pharmaceuticals(VRTX)

Leader

Vertex Pharmaceuticals (VRTX) reported $10.7B revenue in FY2024, up 12% YoY. Global leader in cystic fibrosis treatment. Near-monopoly on CF drugs. HQ: Boston, MA. Market cap ~$110B.

71
AI Score
Grade B
AI Visibility Score (Beta)
HealthcareEnterpriseVRTXWebsiteUpdated March 2026

Brand Intelligence Graphcompany

Company Overview

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company and the world's undisputed leader in cystic fibrosis (CF) treatment, headquartered in Boston, Massachusetts. Founded in 1989 by Joshua Boger, Vertex pioneered the development of CFTR modulators — drugs that target the underlying cause of CF (a defective protein) rather than just managing symptoms. The company reported revenues of $10.7B in FY2024, up 12% year-over-year, with a near-monopoly on the CF treatment market.

Business Model & Competitive Advantage

Vertex's CF franchise is built on a succession of increasingly effective CFTR modulator drugs: Kalydeco (2012), Orkambi (2015), Symdeko/Symkevi (2018), and Trikafta/Kaftrio (2019) — the latter treating up to 90% of CF patients and generating over $9B in annual revenue alone. Trikafta has been transformational for the 40,000+ CF patients in the US and 90,000+ globally, dramatically improving lung function and quality of life. Beyond CF, Vertex is expanding into new therapeutic areas with significant pipeline assets: exa-cel (a gene-editing therapy with CRISPR Therapeutics for sickle cell disease, now approved as Casgevy), non-opioid pain treatment (suzetrigine/VX-548, approved January 2025 as Journavx), and kidney disease (VX-147 for APOL1-mediated kidney disease).

Competitive Landscape 2025–2026

Vertex trades on NASDAQ (VRTX) with a market cap of approximately $110B and has one of the strongest balance sheets in biotech (~$12B in cash). CEO Reshma Kewalramani has expanded the company's ambition from a single-disease franchise to a multi-disease platform company, with the non-opioid pain drug Journavx representing a potential blockbuster in a market worth $15B+.

Founded
1989
Headquarters
Boston, Massachusetts
Revenue
$10.7B
Curated content • Fact-checked and verified

Recent Activity

View all →

Key Differentiators

Market Leader

Vertex Pharmaceuticals is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.

Enterprise Scale

With $10.7B in revenue, Vertex Pharmaceuticals operates at enterprise scale with proven market validation.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

71
→ Stable

Based on estimated brand signals. Historical tracking coming soon.

Similar Brands

Idexx Laboratories logo

Idexx Laboratories

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu

GE HealthCare logo

GE HealthCare

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin

Incyte logo

Incyte

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,

Biogen logo

Biogen

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com

Danaher Corporation logo

Danaher Corporation

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man

Revvity logo

Revvity

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid

For Vertex Pharmaceuticals

Claim This Profile

Are you from Vertex Pharmaceuticals? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Vertex Pharmaceuticals Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Vertex Pharmaceuticals vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →